Constance Keyserling
Chief Operating Officer at ABIONYX PHARMA
Constance Keyserling active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ABIONYX PHARMA | Chief Operating Officer | - | - |
| Corporate Officer/Principal | - | - |
Career history of Constance Keyserling
Former positions of Constance Keyserling
| Companies | Position | Start | End |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
| ESPERION THERAPEUTICS, INC. | Chief Operating Officer | - | - |
| Parke, Davis & Co. LLC | Corporate Officer/Principal | - | - |
QuatRx Pharmaceuticals Co.
 QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - | - |
Training of Constance Keyserling
| Harvard University | Graduate Degree |
Statistics
International
| United States | 6 |
| France | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Chief Operating Officer | 2 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ABIONYX PHARMA | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private companies | 2 |
|---|---|
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Health Technology |
| Parke, Davis & Co. LLC |
- Stock Market
- Insiders
- Constance Keyserling
- Experience
